Get the Stockscreener App
3.06
3.03%
0.09
Abcellera Biologics Inc stock is traded at $3.06, with a volume of 3.69M.
It is up +3.03% in the last 24 hours and up +7.37% over the past month.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
See More
Previous Close:
$2.97
Open:
$3
24h Volume:
3.69M
Relative Volume:
1.37
Market Cap:
$903.82M
Revenue:
$38.03M
Net Income/Loss:
$-146.40M
P/E Ratio:
-5.8846
EPS:
-0.52
Net Cash Flow:
$-121.38M
1W Performance:
+10.47%
1M Performance:
+7.37%
6M Performance:
+3.03%
1Y Performance:
-41.60%
1-Day Range:
$2.96
$3.14
1-Week Range:
$2.81
$3.14
52-Week Range:
$2.335
$5.62
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
2215 YUKON STREET, VANCOUVER
Compare ABCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
3.06 | 903.82M | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
Abcellera Biologics Inc (ABCL-Q) QuotePress Release - The Globe and Mail
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025 - Business Wire
AbCellera Biologics Inc. (NASDAQ:ABCL) most popular amongst individual investors who own 36% of the shares, institutions hold 29% - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 10.5%Time to Buy? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6.7%What's Next? - MarketBeat
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Trading Up 10.5%What's Next? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Down 6.7%Here's Why - MarketBeat
Geode Capital Management LLC Has $295,000 Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology - sharewise
AbCellera and AbbVie expand oncology collaboration - Investing.com
AbCellera and AbbVie expand oncology collaboration By Investing.com - Investing.com South Africa
AbCellera Biologics (NASDAQ:ABCL) Price Target Cut to $4.00 by Analysts at KeyCorp - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 7.9%What's Next? - MarketBeat
Is AbCellera Biologics Inc. (ABCL) Among the Best Canadian Penny Stocks to Buy According to Analysts? - Insider Monkey
12 Best Canadian Penny Stocks to Buy According to Analysts - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Trading Up 7.2%Time to Buy? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6%What's Next? - MarketBeat
AbCellera Biologics: Still A Concept Stock (NASDAQ:ABCL) - Seeking Alpha
Is AbCellera Biologics (NASDAQ:ABCL) In A Good Position To Invest In Growth? - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Trading Up 3.3%Should You Buy? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Gap UpHere's What Happened - MarketBeat
Walleye Capital LLC Makes New $668,000 Investment in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics (FRA:8QQ) Price-to-Owner-Earnings : (As of Dec. 07, 2024) - GuruFocus.com
PDT Partners LLC Sells 173,884 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera's SWOT analysis: biotech firm's stock faces pivotal year By Investing.com - Investing.com Canada
AbCellera's SWOT analysis: biotech firm's stock faces pivotal year - Investing.com India
AbCellera Biologics (FRA:8QQ) Degree of Operating Leverage : -1.44 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Net Issuance of Debt : $3.95 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Pre-Tax Income : $-202.17 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Capex-to-Revenue : 2.85 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Buildings And Improvements : $66.92 Mil (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
US Penny Stocks To Consider In November 2024 - Simply Wall St
ABCL (AbCellera Biologics) Revenue per Share : $0.11 (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Change In Receivables : $-64.70 Mil (TTM As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Debt-to-Equity : 0.07 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) Owner Earnings per Share (TTM) : -0.61 (As of Sep. 2024) - GuruFocus.com
AbCellera to Present at Upcoming Investor Conferences in December and January - Devon Dispatch
AbCellera to Present at Major Healthcare Conferences: Piper Sandler and JPM 2024-25 - StockTitan
ABCL (AbCellera Biologics) Goodwill-to-Asset : 0.03 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) EBIT per Share : $-1.00 (TTM As of Sep. 2024) - GuruFocus.com
GSA Capital Partners LLP Boosts Stock Position in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Baillie Gifford & Co. - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Bloom Burton Cuts Earnings Estimates for AbCellera Biologics - MarketBeat
Adv Micro Devices (AMD-Q) QuotePress Release - The Globe and Mail
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):